Lukasiewicz, E.

patient response model treatment t-cell therapy hepatitis hcv-rna hepatitis c study hcv-speci 8 model value fi rst month ribavirin frequency hla-a peptide genotype signi analysis t-cell lines baseline result t-cell response hla-a 2 kinetic non-rvr proliferative t-cell responses expansion measurement prediction virological response outcome peginterferon figure proliferative interferon week 12 pa index index –liver pancreas hepatitis c virus week 12 algorithm tetramer ficant group virus virological pa indices difference algorithm limit 48 weeks combination therapy 12 weeks rvr patients control non-rvr patients point trial 12 model ifn -␥ production cd 8 analysis 0-w model cytotoxic decline signi ficant nonsustained virological response cd 8 cells 15- mer peptides score staining treatment outcome hcv-rna measurements viremia effect accuracy t-cell responses signi ficantly